Celcuity Inc. (CELC) — Quarterly Report

Key Insights

• The filing contains only structural XML metadata without substantive financial data, balance sheets, income statements, or management discussion and analysis that would typically comprise a 10-Q filing.
• Multiple equity offerings are referenced including July 2025 common stock and prefunded warrant offerings, plus convertible notes, indicating recent capital raises to fund operations.
• The company has complex debt structure with multiple term loans (Term D, E, E2, F, F2, G) from Innovatus Life Sciences as of September 2025, suggesting reliance on debt financing alongside equity offerings.
• Various stock-based compensation instruments are in place including options, restricted stock, and employee stock purchase plans across multiple periods, indicating typical pre-clinical/early-stage biotech capital structure.